AlphaYou
Overview
Smart money at a glance
Filings to Oct 13, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
Market overview
Fundamentals Oct 13- Open
- $2.81
- 52-wk high
- $1,210.00
- High
- $2.93
- 52-wk low
- $2.53
- Low
- $2.64
- Prev close
- $2.75
- Mkt cap
- $2.2M
- Volume
- 202.3K
- Beta
- -0.97
- P/B
- 0.2x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -203.9%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about GNPX filings
Are insiders buying or selling Genprex Inc (GNPX) stock?
Neither. Genprex Inc (GNPX) insiders filed no open-market purchases or sales in the 90 days to Oct 13, 2026, according to SEC Form 4 filings.
Which members of Congress have traded GNPX recently?
None. No member of Congress disclosed a GNPX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this GNPX smart-money data?
This summary uses filings available on Oct 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
2 funds hold a position.
What Congress is doing
How top traders are positioned
No tracked top-trader positions in GNPX right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No reported figure for the latest quarter.
Company release linked above, where available
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 13, 2026 | Unavailable | - | Unavailable | Unavailable |
| Mar 31, 2026 | May 13, 2026 | Unavailable | - | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 30, 2026 | Unavailable | - | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 14, 2025 | -$5.00 / -$0.65Alpha Vantage | -$4.35 miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 14, 2025 | -$8.47 / -$0.74Alpha Vantage | -$7.73 miss | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 7, 2025 | $2.58 / -$0.39Alpha Vantage | +$2.97 beat | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 31, 2025 | -$0.42 / -$0.39Alpha Vantage | -8.77% miss | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 13, 2024 | -$1353.00 / -$3003.00Alpha Vantage | +54.95% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 13, 2026, in 31 days
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Market cap
- $2M
Valuation
- P/B0.21
Quality
- Operating margin0.0%
- ROE-203.9%
- ROA-94.5%
Growth
- Beta-0.97
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace